Advice4u.com

FDA Approves New Labeling For ISENTRESS® To Include 96-Week Efficacy And Tolerability Data In Adult Patients Infected With HIV-1

August 6, 2010 – 7:21 pm

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for ISENTRESS® (raltegravir) tablets to include 96-week data, which demonstrates the durable efficacy of ISENTRESS in HIV-1 infected patients. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The new labeling for ISENTRESS is based on analyses of plasma HIV-1 RNA levels through 96 weeks in three double-blind controlled clinical studies of ISENTRESS…

Find more info about FDA Approves New Labeling For ISENTRESS® To Include 96-Week Efficacy And Tolerability Data In Adult Patients Infected With HIV-1 photos videos pictures. read more

Related Info :

Tags: 96Week, adult, Adult Patients, Adults, Antiretroviral Agents, Approves, Data, Efficacy, Fda, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Hiv, Hiv Infection, HIV1, Include, Infected, Isentress, ISENTRESS®, Labeling, Merck, Patients, Photos, Plasma Hiv, Rna Levels, Tolerability, Treatment Of Hiv